JAK1 and Recurrent upper respiratory tract infections: Japan just approved delgocitinib ointment for both pediatric and adult AD. Oral JAKi include baricitinib (JAK1/2), abrocitinib (JAK1), and upadacitinib (JAK1). All three met the primary and secondary goals of numerous trials for moderate-to-severe AD. The mild-to-moderate TEAEs included acne, nausea, headaches, upper respiratory tract infections, and to a lesser extent, herpes infection and certain test abnormalities. JAKi has a great deal of potential as the subsequent phase of targeted AD therapy.